Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV_IMPACT: ABRYSVO Vaccine in Pregnant Women for RSV Prevention in Infants
NCT06955728Phase 3Recruiting
- Sponsor
- University of the Witwatersrand
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Placebo with ABRYSVO (2 arms). Primary endpoints: Efficacy against RSV-A or RSV-B subtype confirmed severe LRTI at 180 days and Occurrence of preterm births (<37 weeks GA). Started Sep 2025; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06955728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955728.